Methylphenidate and indomethacin induced visual hallucination: a case report

References (15)

1. Kaplan G, Newcorn JH. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin North Am 2011
2. Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother 2014
3. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol Suppl 1996
4. Clavenna A, Bonati M. Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD. Expert Opin Drug Saf 2017
5. Gross-Tsur V, Joseph A, Shalev RS. Hallucinations during methylphenidate therapy. Neurology 2004
6. Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2006
7. Halevy A, Shuper A. Methylphenidate induction of complex visual hallucinations. J Child Neurol 2009
8. Porfirio MC, Giana G, Giovinazzo S, Curatolo P. Methylphenidateinduced visual hallucinations. Neuropediatrics 2011
9. Martinez-Aguayo JC, Arancibia M, Meza-Concha N, Bustamante C, Perez-Bracchiglione J, Madrid E. Brief psychosis induced by methylphenidate in a child with attention deficit disorder: a case report and literature review. Medwave 2017
10. e6980. 10. Mosholder AD, Gelperin K, Hammad TA, Phelan K, JohannLiang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics 2009
11. Man KK, Coghill D, Chan EW, Lau WC, Hollis C, Liddle E, Banaschewski T, McCarthy S, Neubert A, Sayal K, Ip P, Wong IC. Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system. Transl Psychiatry 2016
12. e956. 12. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, Ding Y, Gatley SJ, Gifford A, Franceschi D. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001
13. RC121. 13. Groenman AP, Schweren LJ, Dietrich A, Hoekstra PJ. An update on the safety of psychostimulants for the treatment of attentiondeficit/hyperactivity disorder. Expert Opin Drug Saf 2017
14. Onder G, Pellicciotti F, Gambassi G, Bernabei R. NSAID-related psychiatric adverse events: who is at risk? Drugs 2004
15. Braddock LE, Heard RN. Visual hallucinations due to indomethacin: a cas